Valion Bio Reports Clean Entolimod Safety Data, Advancing to Fully Funded AFRRI Efficacy Study
VBIO is trading near its 52-week low of $0.663 (1.9% above the low) on light trading volume (0.3× avg).
Summary
Valion Bio's Entolimod showed no treatment-related toxicity in the NIAID/AFRRI safety study, clearing the way for a fully funded AFRRI study of survival and GI recovery after radiation exposure.
Key Events · Product Development and Regulatory · VBIO
-
Entolimod Safety Study Clears
In the AFRRI study, 20 male C57BL/6 mice received a single 0.72 mg/kg subcutaneous dose of Entolimod or saline and were observed for 14 days; investigators found no evidence of treatment-related toxicity.
-
No Toxicity Across Key Panels
Body weight showed no statistically significant overall difference versus control (p = 0.1424), hematologic parameters stayed within normal reference ranges, and serum chemistry (BUN, creatinine, AST, ALT, ALP, glucose, total protein) showed no significant differences.
-
Next Study Fully Funded
AFRRI is planning a fully funded therapeutic study in a GI-ARS mouse model evaluating survival and gastrointestinal tissue recovery after radiation exposure; the company did not state a start date or readout timeline.
-
Cash Still the Constraint
The advance is externally funded, but the company previously disclosed going-concern doubt with cash of $2.1M as of the 2026-08-14 10-Q, and a $100M shelf with a $5M ATM was registered on 2026-10-08.
Analysis · VBIO · Life Sciences
Entolimod has cleared its government-funded safety phase with no treatment-related toxicity, no hematologic disruption and normal organ-function panels in the AFRRI mouse study. That moves the lead asset into a fully funded therapeutic study measuring survival and GI recovery after radiation exposure — the endpoints that matter for an FDA Animal Rule filing. For a company that previously disclosed going-concern doubt and cash of $2.1M, the value here is that the next study is externally funded, so pipeline progress does not consume the thin balance sheet. The readout is preclinical and the timeline for the efficacy data is not stated, so this de-risks the program without changing the near-term cash picture.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.66 to $70.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.